Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.

JAMA oncology - 1 Sept 2016

Sacher Adrian G, Gandhi Leena

Abstract excerpt

IMPORTANCE: The development of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) checkpoint inhibitors has changed the landscape of non-small-cell lung cancer (NSCLC) therapy, with 2 approvals from the US Food and Drug Administration of PD-1 inhibitors for second-line therapy. However, the rational use of these agents has been limited by the lack of a definitive predictive biomarker. OBSERVATIONS: Tumor PD-L1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to B7-H1 Antigen
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Polymerase III

Share to MutS Homolog 2 Protein

Share to Nivolumab

Share to Poly-ADP-Ribose Binding Proteins

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 27310809
DOI: 10.1001/jamaoncol.2016.0639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.PMID 27310809Read ↗

PD-L1 as a biomarker in NSCLC: challenges and future directionsSemantic proximity Read ↗

Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.Semantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

PD-L1 Expression in NSCLC: Clouds in a Bright SkySemantic proximity Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.Semantic proximity Read ↗

Shedding light on the molecular determinants of response to anti-PD-1 therapy.Semantic proximity Read ↗

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity Read ↗

Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?Semantic proximity Read ↗

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.